MGMT and central nervous system cancer: In grade 4 gliomas, methylation status of MGMT (O-6-Methylguanine-DNA Methyltransferase) gene promoter has been identified as a robust and independent predictive factor for the response to temozolomide, the first-line chemotherapy for grade 4 gliomas [14].